Earnings Presentations
Apr 25, 2023
Feb 15, 2023
Oct 25, 2022
Jul 20, 2022
May 03, 2022
Investor R&D Day 2021
Sep 21, 2021
Sep 21, 2021
Sep 21, 2021
Sep 21, 2021
Sep 21, 2021
Sep 21, 2021
Sep 21, 2021
Sep 21, 2021
Sep 21, 2021
Sep 21, 2021
Conference and Other Investor Presentations
Dec 06, 2022
Jan 13, 2022
Jun 08, 2021
Oct 22, 2019
Jun 05, 2019
Mar 04, 2019
Dec 12, 2018
Jun 28, 2018
Medical and Scientific Conference Presentations
Evaluating Efficacy and Safety of Tofersen in Adults with SOD1-ALS: Results from the Phase 3 VALOR Trial and Open-Label Extension at ENCALS
Jun 03, 2022
View Presentation 2.4 MB
Subgroup Analyses of the Plasma P-tau181 Population From EMERGE/ENGAGE, Phase 3 Clinical Trials Evaluating Aducanumab in Early Alzheimer’s Disease at AD/PD
Mar 18, 2022
View Presentation 649.7 KB
Heterogeneity in Symptom Progression and Treatment Response: An Analysis of Participants with Early Alzheimer’s Disease from the EMERGE Aducanumab Trial at AD/PD
Mar 18, 2022
View Presentation 486 KB
Evaluating the Evidence of Aducanumab Treatment Benefit Using Standardized Test Statistics and Global Statistical Tests at AD/PD
Mar 18, 2022
View Presentation 376.8 KB
Effect of Reduction in Brain β-Amyloid Levels on Cognitive Decline in Randomized Clinical Trials: An Updated Instrumental Variable Meta-Analysis at AD/PD
Mar 18, 2022
View Presentation 621.9 KB
Key Milestones in Alzheimer’s Disease at AD/PD
Mar 16, 2022
View Presentation 2.6 MB
Aducanumab Phase 3 Studies: Exposure-Response Analysis Evaluating the Relationship Between Amyloid Removal and Slowing of Clinical Decline on CDR-SB Scores at AD/PD
Mar 15, 2022
View Presentation 183.2 KB
Dose and time dependent changes in plasma ptau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials at CTAD
Nov 11, 2021
View Presentation 778.4 KB
Baseline EMBARK data from EMERGE, ENGAGE, and PRIME participants in the EMBARK re-dosing study at CTAD
Nov 09, 2021
View Presentation 425 KB
Results from the Phase 3 VALOR study and its open-label extension at ANA 2021 View Presentation
Oct 17, 2021
View Presentation 934.2 KB
ICARE AD-US: Design of a Prospective, Single-arm, Multicenter, Noninterventional Real-world Study of Aducanumab in United States
Jul 29, 2021
View Presentation 438.6 KB
🔈 Listen to Audio 19.3 MB
Reduction in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment with Aducanumab Were Associated with Slowing Clinical Decline
Jul 26, 2021
View Presentation 365.9 KB
🔈 Listen to Audio 7.1 MB
Subgroup Analyses of the Amyloid PET Substudies from EMERGE and ENGAGE, Phase 3 Clinical Trials Evaluating Aducanumab in Patients with Early Alzheimer’s Disease
Jul 26, 2021
View Presentation 294 KB
🔈 Listen to Audio 6.6 MB
Considerations for the Real-World Management of ARIA from the Aducanumab Phase 3 Studies EMERGE and ENGAGE
Jul 26, 2021
View Presentation 241 KB
🔈 Listen to Audio 7.6 MB
Item-level Analysis of Clinical Measures in Patients with Early Symptomatic Alzheimer’s Disease Following Treatment with High-Dose Aducanumab in the Phase 3 Study EMERGE
Jul 26, 2021
View Presentation 231.3 KB
🔈 Listen to Audio 7.6 MB
Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Lumbar Intrathecal Bolus Administrations of Antisense Oligonucleotide (ISIS 814907; BIIB080) Targeting Tau mRNA in Patients with Mild Alzheimer’s Disease
Jul 26, 2021
View Presentation 321.6 KB
🔈 Listen to Audio 3.1 MB
Aducanumab EMBARK study design poster at AAN 2021
Apr 17, 2021
View Presentation 442 KB
Aducanumab EMBARK study design audio presentation at AAN 2021
Apr 17, 2021
Listen to Audio 3.6 MB
Evaluation of aducanumab safety in early Alzheimer’s disease at AD/PD
Mar 13, 2021
View Presentation 305.7 KB
Evaluation of aducanumab efficacy in early Alzheimer’s disease at AD/PD
Mar 13, 2021
View Presentation 793.4 KB
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD
Mar 10, 2021
View Presentation 480.1 KB
Aducanumab data review with Global Alzheimer's Platform Foundation
Feb 23, 2021
View Presentation 2.4 MB
Aducanumab data review and Q&A with Alzheimer's Disease International
Jan 14, 2021
View Presentation 2.2 MB
Aducanumab EMBARK study design at CTAD 2020
Nov 04, 2020
View Presentation 751.9 KB
Aducanumab Phase 3 Topline Results at the AAN 2020 Science Highlights (encore virtual presentation)
Sep 23, 2020
View Presentation 473.1 KB
Aducanumab Phase 3 Topline Results at the 23rd Chinese National Conference of Neurology (encore virtual presentation)
Sep 19, 2020
View Presentation 795 KB
A Biogen Perspective on Drug Development for Neurological Diseases: The Example of Alzheimer’s Disease
Aug 31, 2020
View Presentation 1.5 MB
Aducanumab Phase 3 Topline Results at AAIC (encore virtual presentation)
Jul 29, 2020
View Presentation 512.4 KB
Aducanumab Phase 3 Topline Results at AAN (encore virtual presentation)
May 18, 2020
View Presentation 775.1 KB
Aducanumab Phase 3 Topline Results at AAT-AD/PD (encore presentation)
Apr 02, 2020
View Presentation 1.1 MB
Aducanumab Phase 3 Topline Results at CTAD
Dec 05, 2019
View Presentation 1.6 MB
Safety, PK, PD, and Exploratory Efficacy in Single and Multiple Dose Study of a SOD1 Antisense Oligonucleotide (BIIB067) Administered to Participants With ALS
May 07, 2019
View Presentation 11.5 MB
CTAD Oral Presentation: Aducanumab Titration Dosing Regimen: 36-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer’s Disease
Oct 26, 2018
View Presentation 254.1 KB
CTAD Keynote: What Have We Learned from Aducanumab?
Oct 25, 2018
View Presentation 2.7 MB
Cumulative Aducanumab Safety Data from PRIME: A Randomized, Double-blind, Placebo-controlled, Phase 1b Study
Oct 24, 2018
View Presentation 244 KB
Aducanumab 48-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer’s Disease
Oct 24, 2018
View Presentation 355.1 KB
24-Month Analysis of APOE ε4 Carriers in PRIME, a Randomized Phase 1B Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
Jul 22, 2018
View Presentation 222.5 KB
24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
Jul 22, 2018
View Presentation 927.9 KB
Aducanumab Titration Dosing Regimen: 24-Month Interim Analysis from PRIME, a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease
Apr 22, 2018
View Presentation 432.4 KB
Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease
Apr 22, 2018
View Presentation 450.4 KB
The Importance of Early Identification and Treatment of Alzheimer’s Disease
Mar 15, 2018
View Presentation 1.9 MB
NUSINERSEN CHERISH Final Results (Poster & Presentation) Ph3 AAN 2017
Apr 25, 2017
Source
AAN, April 25, 2017
View Presentation 1 MB
NUSINERSEN NURTURE Interim Results (Presentation) Ph3 AAN 2017
Apr 25, 2017
Source
AAN, April 25, 2017
View Presentation 915.6 KB
NUSINERSEN ENDEAR Final Results (Presentation) Ph3 AAN 2017
Apr 24, 2017
Source
AAN, April 24, 2017
View Presentation 1 MB
Annual Stockholder Presentation
Hemophilia Spin-off Presentations
January 6, 2017
May 3, 2016